Search

Your search keyword '"Fiorentino, Michelangelo"' showing total 1,236 results

Search Constraints

Start Over You searched for: Author "Fiorentino, Michelangelo" Remove constraint Author: "Fiorentino, Michelangelo"
1,236 results on '"Fiorentino, Michelangelo"'

Search Results

52. An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre Experience

53. Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer

54. Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

55. Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

56. Abstract 737: Variation in prognostic value of Gleason score for lethal prostate cancer using time-varying area under the curve

57. Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

59. Supplementary Figure 1 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

60. Supplementary Figure 4 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

62. Supplementary Figure 2 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

64. Supplementary Figure 3 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

66. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions

67. Supplementary Data from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

68. Data from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

69. Supplementary Table 1 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum

72. The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome

75. Supplementary Table 4 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

76. Supplementary Figure 1 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

78. Supplementary Table 3 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

79. Supplementary Table 3 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

80. Data from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

81. Supplementary Table 1 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

82. Data from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

84. Supplementary Figure 1 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

85. Supplementary Table 2 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

86. Supplementary Tables 1, 2, 4 and 5 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

87. Data from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

88. Supplementary Table S1 from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

93. Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging

94. Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma?

99. FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal‐type.

Catalog

Books, media, physical & digital resources